



**SYNCOM**  
Healthcare Limited

Date: 14.02.2019

To, The Corporate Relationship Department, BSE Limited, Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai – 400 001	To, The Secretary, National Stock Exchange of India Limited, Exchange Plaza, Bandra Kurla Complex, Bandra (East), Mumbai 400051
BSE Scrip Code:533157	NSE Scrip : SYNCOM ISIN No.: INE602K01014

**Subject:- Outcome of Board Meeting held on 14<sup>th</sup> February 2019 in terms of Regulations 30 of SEBI (Listing Obligation and Disclosure Requirement), 2015**

Dear Sir,

This is to inform you that as per Regulation 33 read with part A of Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the Board of Directors of the Company at its meeting held today i.e. 14<sup>th</sup> February 2019 on Thursday at 05:00 p.m. at the registered office of the Company and concluded at 06:30 p.m. considered, approved and adopted unaudited standalone financial results of the Company for the third quarter and nine months ended on 31<sup>st</sup> December, 2018.

A copy of the statement of the unaudited standalone financial results alongwith the Limited Review Report are enclosed as an **Annexure A**.

The above information will be made available on the Company's website [www.syncom.in](http://www.syncom.in)

Request you to take the same on record.

For Syncom Healthcare Limited

Charu Srivastava  
Company Secretary  
M.No.- A27108



CIN : L51397MH2002 PLC136652



Regd. Office : 502 Advent Atria, Chincholi Bunder, Malad (W)  
Mumbai - 400064 INDIA. Tel : +91 (022) 2881 3796 / 97

Works : D - 42 IIE Sidcul Selaqui, Dehradun - 248197 Uttarakhand, INDIA  
Tel : +91 07060008770 / 07060088770 Website : [www.syncom.in](http://www.syncom.in)



# S. G. KABRA & CO.

## CHARTERED ACCOUNTANTS

Wavell House, 1st Floor, 1st Dhobi Talao Lane, Mumbai - 400 002.

Tel.: 2201 0708 / 2200 4533 • Fax : 2200 1497 • E-mail : info@sgkabra.com • Website : www.sgkabra.com

### Limited Review Report

To,  
Board of Directors,  
Syncom Healthcare Limited

1. We have reviewed the accompanying statement of unaudited standalone financial results ('Statements') of **M/s Syncom Healthcare Limited** (the Company) for the quarter ended 31<sup>st</sup> December, 2018, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. This Statement is the responsibility of the Company's Management and has been approved by the Board of Directors.

This statement is the responsibility of the Company's Management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to issue a report on the Statement based on our review.

2. We conducted our review in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
3. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement prepared in accordance with the applicable Indian (specified under Section 133 of the Companies Act, 2013 and SEBI Circulars CIR/CFD/CMD/15/2015 dated 30 November 2015 and CIR/CFD/FAC/62/2016 dated 5 July 2016, and other recognized accounting practices and policies has not disclosed the information required to be disclosed in



accordance with the requirements of Regulation 33 of the SEBI ( Listing Obligation and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

**For S. G. Kabra & Company**

Chartered Accountants

ICAI Firm Registration Number: 104507W



**Malvika P Mitra**

Partner

Membership No. 44105

**Place:** Mumbai

**Date-** 14/02/2019



Regd. Off. : 502, Advent Atria, Chincholi Bunder Road, Opp Kingston Complex, Malad (West), Mumbai- 400 064.

STATEMENT OF STANDALONE UNAUDITED FINANCIAL RESULT FOR THE QUARTER AND NINE MONTHS ENDED ON DECEMBER 31, 2018							
(Rs. in Lakh)							
Sr. No	Particulars	3 months ended 31-12-2018 (Unaudited)	3 months ended 30-09-2018 (Unaudited)	3 months ended 31-12-2017 (Unaudited)	9 months ended 31-12-2018 (Unaudited)	9 months ended 31-12-2017 (Unaudited)	Year ended 31-03-2018 (Audited)
1	Income						
a	Revenue from operations	1,749.46	1,496.99	1,217.19	4,538.58	2,986.27	4,184.56
b	Other income	16.34	0.88	2.99	24.73	23.89	38.83
	<b>Total income</b>	<b>1,765.80</b>	<b>1,497.87</b>	<b>1,220.18</b>	<b>4,563.31</b>	<b>3,010.16</b>	<b>4,223.38</b>
2	Expenses						
a	Cost of materials consumed	1,057.27	832.15	586.24	2,487.23	1,617.84	2,271.33
b	Purchases of stock-in-trade	-	-	-	-	-	-
c	Changes in inventories of finished goods, work-in-progress and stock-in-trade	(68.71)	29.35	58.29	103.60	317.72	148.34
d	Employee benefit expense	304.23	296.88	273.59	887.51	761.98	1,066.41
e	Finance costs	5.26	3.38	1.85	12.88	25.66	28.04
f	Depreciation, depletion and amortisation expense	75.16	73.93	95.84	221.99	281.80	373.87
g	Other Expenses	421.13	337.73	330.17	1,099.33	865.20	1,214.44
	<b>Total expenses</b>	<b>1,794.34</b>	<b>1,573.44</b>	<b>1,345.99</b>	<b>4,812.54</b>	<b>3,870.20</b>	<b>5,102.43</b>
3	<b>Total profit before exceptional items and tax</b>	<b>(28.55)</b>	<b>(75.56)</b>	<b>(125.81)</b>	<b>(249.23)</b>	<b>(860.04)</b>	<b>(879.05)</b>
4	Exceptional items	(0.00)	(0.40)	-	(8.10)	5,663.67	5,673.27
5	<b>Total profit before tax</b>	<b>(28.55)</b>	<b>(75.17)</b>	<b>(125.81)</b>	<b>(241.13)</b>	<b>(6,523.72)</b>	<b>(6,552.32)</b>
6	Tax expense						
a	Current tax	-	-	-	-	-	-
b	Deferred tax	-	-	-	-	-	-
	<b>Total tax expenses</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>
7	<b>Total profit (loss) for period</b>	<b>(28.55)</b>	<b>(75.17)</b>	<b>(125.81)</b>	<b>(241.13)</b>	<b>(6,523.72)</b>	<b>(6,552.32)</b>
8	<b>Other comprehensive income net of taxes</b>	<b>-</b>	<b>-</b>	<b>1.84</b>	<b>-</b>	<b>5.51</b>	<b>(1.98)</b>
(A)(i)	Items that will not be reclassified to Profit & Loss	-	-	-	-	-	-
(A)(ii)	Income Tax relating to items that will not be reclassified to Profit & Loss	-	-	-	-	-	-
(B)(i)	Items that will be reclassified to Profit & Loss	-	-	-	-	-	-
(B)(ii)	Income Tax relating to items that will be reclassified to Profit & Loss	-	-	-	-	-	-
	<b>Total other comprehensive income net of taxes</b>	<b>-</b>	<b>-</b>	<b>1.84</b>	<b>-</b>	<b>5.51</b>	<b>(1.98)</b>
9	<b>Total Comprehensive Income (loss) for the period</b>	<b>(28.55)</b>	<b>(75.17)</b>	<b>(127.64)</b>	<b>(241.13)</b>	<b>(6,529.22)</b>	<b>(6,550.34)</b>
10	Details of equity share capital						
a	Paid-up equity share capital	4,000.00	4,000.00	4,000.00	4,000.00	4,000.00	4,000.00
b	Face value of equity share capital	10.00	10.00	10.00	10.00	10.00	10.00
11	<b>Other Equity</b>	<b>(3,194.04)</b>	<b>(3,165.50)</b>	<b>(2,919.68)</b>	<b>(3,194.04)</b>	<b>(2,919.68)</b>	<b>(2,952.90)</b>
12	Earnings per share in Rs.						
i	Basic earnings (loss) per share from continuing operations in Rs.	(0.07)	(0.19)	(0.32)	(0.60)	(16.32)	(16.38)
ii	Diluted earnings (loss) per share from continuing operations in Rs.	(0.07)	(0.19)	(0.32)	(0.60)	(16.32)	(16.38)

**NOTES**

- The above financial results for the quarter / nine months ended December, 31, 2018 were reviewed by the Audit Committee on 14th February, 2019 and thereafter approved and taken on record by the Board of Directors at their meeting held on 14th February, 2019.
- The statement has been prepared in accordance with the Companies ( Indian Accounting Standard ) Rules, 2015 (Ind AS) prescribed under section 133 of Companies Act, 2013 and other recognised accounting practices and policies and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements), Regulations 2015.
- The Company operates in single business segment i.e. "Pharmaceutical Formulations"
- The Government of India introduced the Goods and Service Tax [GST] with effect from July 1, 2017 which replaced excise duty and various other indirect taxes. As required under Ind AS, Revenue from operations for the quarter and nine months ended December 31, 2018 is reported net of GST. Revenue from operations for the periods upto June 30, 2017 was reported inclusive of excise duty, which is now subsumed in GST.
- The unaudited Standalone financial results of the Company for the quarter and nine months ended December 31, 2018 are available on the Company's website i.e. www.syncom.in and also available on website of stock exchange i.e. www.bseindia.com and www.nseindia.com
- Previous quarter figures have been regrouped / rearranged wherever considered necessary.
- There are no exceptional items.

For Syncom Healthcare Limited

  
Ajay Bankda  
Managing Director  
DIN : 00013796

Place : Mumbai  
Date : 14.02.2019